GSK’s application to expand use of Nucala (mepolizumab) for the treatment of COPD accepted for revie

GSK’s application to expand use of Nucala (mepolizumab) for the treatment of COPD accepted for review by the European Medicines Agency

Nucala (mepolizumab) could be the first biologic with monthly dosing for patients with COPD, if approved

RSS Hunter • Mar 24, 2025